On this page
Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension
neomycin and polymyxin B sulfates and hydrocortisone otic · Suspension
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Aminoglycoside Antibacterial [EPC] | EPC | All 66 members |
| Aminoglycosides [CS] | CS | All 66 members |
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
| Polymyxin-class Antibacterial [EPC] | EPC | All 55 members |
| Polymyxins [CS] | CS | All 55 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 060613-001 | CASPORYN HC | SUSPENSION/DROPS | HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE | Prescription | AT | RLD |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 14 | Manufacturing (CMC) | Approved | March 15, 2019 | Standard |
| Supplement | 13 | Labeling | Approved | December 19, 2017 | Standard |
| Supplement | 9 | Labeling | Approved | August 10, 2000 | — |
| Supplement | 8 | Labeling | Approved | August 10, 2000 | — |
| Supplement | 10 | Manufacturing (CMC) | Approved | July 23, 1999 | — |
| Supplement | 7 | Manufacturing (CMC) | Approved | February 14, 1995 | — |
| Supplement | 5 | Labeling | Approved | March 30, 1993 | — |
| Supplement | 4 | Labeling | Approved | February 4, 1988 | — |
| Original application | 1 | Approved | May 25, 1975 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260804). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Therapy with this product should be limited to 10 consecutive days. The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator. For adults, 4 drops of the suspension should be instilled into the affected ear 3 or 4 times daily. For children, 3 drops are suggested because of the smaller capacity of the ear canal. The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear. If preferred, a cotton wick may be inserted into the canal and then the cotton may be saturated with the suspension. This wick should be kept moist by adding further suspension every 4 hours. The wick should be replaced at least once every 24 hours. SHAKE WELL BEFORE USING.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS This product is contraindicated in those individuals who have shown hypersensitivity to any of its components, and in herpes simplex, vaccinia, and varicella infections.
Warnings
openFDA Drug LabelingWARNINGS Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk is greater with prolonged use. Therapy should be limited to 10 consecutive days (see PRECAUTIONS-General ). Patients being treated with eardrops containing neomycin should be under close clinical observation. Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension should not be used in any patient with a perforated tympanic membrane. Discontinue promptly if sensitization or irritation occurs. Neomycin sulfate may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical neomycin is not known. When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis externa or stasis dermatitis, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is usually a low-grade reddening with swelling, dry scaling, and itching; it may be manifest simply as a failure to heal. Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin containing applications should be avoided for the patient thereafter.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS ). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear. To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharmaceuticals, Inc. at 1-866-562-4597 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Description
openFDA Drug LabelingDESCRIPTION Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Suspension, USP is a sterile antibacterial and anti-inflammatory suspension for otic use. Each mL contains: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, and hydrocortisone 10 mg (1%). The vehicle contains thimerosal 0.01% (added as a preservative) and the inactive ingredients cetyl alcohol, propylene glycol, polysorbate 80, and Water for Injection. Sulfuric acid may be added to adjust pH. Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 mcg of neomycin standard per mg, calculated on an anhydrous basis. The structural formulae are: Polymyxin B sulfate is the sulfate salt of polymyxin B1 and B2, which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are: Hydrocortisone, 11β, 17, 21-trihydroxypregn-4-ene-3, 20-dione, is an anti-inflammatory hormone. Its structural formula is: struct1 struct2 struct3
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED 10 mL bottle (NDC 68788-7787-1). Store at 15° to 25°C (59° to 77°F). Rx only KEEP OUT OF REACH OF CHILDREN. Distributed by: Rising Pharma Holdings, Inc. East Brunswick, NJ 08816 Code No.: TS/DRUGS/13/2010 Made in India PIA44801-03 Revised: 05/2024 P1537072
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: HYDROCORTISONE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-6336-0 | 50090-6336 | A-S Medication Solutions | 1 BOTTLE in 1 CARTON (50090-6336-0) / 10 mL in 1 BOTTLE | January 18, 2023 |
| 68788-7787-1 | 68788-7787 | Preferred Pharmaceuticals, Inc. | 1 BOTTLE in 1 CARTON (68788-7787-1) / 10 mL in 1 BOTTLE | October 21, 2020 |
| 64980-448-01 | 64980-448 | Rising Pharma Holdings, Inc. | 1 BOTTLE in 1 CARTON (64980-448-01) / 10 mL in 1 BOTTLE | March 15, 2019 |
| 50090-6336 | 50090-6336 | A-S Medication Solutions | — | March 15, 2019 |
| 68788-7787 | 68788-7787 | Preferred Pharmaceuticals, Inc. | — | October 21, 2020 |
| 64980-448 | 64980-448 | Rising Pharma Holdings, Inc. | — | March 15, 2019 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.